VistaGen Therapeutics Receives Notice of Allowance for U.S. Patent for Treatment of Depression with PH10
VistaGen Therapeutics Receives FDA Fast Track Designation for Development of AV-101 as a Non-Opioid Treatment for Neuropathic Pain
VistaGen Therapeutics Acquires Worldwide License of Phase 3-Ready CNS Drug Candidate from Pherin Pharmaceuticals
Eagle Energy Metals Corp. and Spring Valley Acquisition Corp. II Announce Effectiveness of Registration Statement and Record and Meeting Dates for Extraordinary General Meeting of Shareholders to Approve Proposed Business Combination
